| __timestamp | Eli Lilly and Company | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 1860000 |
| Thursday, January 1, 2015 | 6533000000 | 2963000 |
| Friday, January 1, 2016 | 6452000000 | 6961000 |
| Sunday, January 1, 2017 | 6588100000 | 11779000 |
| Monday, January 1, 2018 | 5975100000 | 13697000 |
| Tuesday, January 1, 2019 | 6213800000 | 15749000 |
| Wednesday, January 1, 2020 | 6121200000 | 18638000 |
| Friday, January 1, 2021 | 6431600000 | 27196000 |
| Saturday, January 1, 2022 | 6440400000 | 31739000 |
| Sunday, January 1, 2023 | 6941200000 | 33491000 |
| Monday, January 1, 2024 | 8593800000 |
Unleashing the power of data
In the world of pharmaceuticals, managing costs is as crucial as innovation. This chart compares the Selling, General, and Administrative (SG&A) expenses of Eli Lilly and Company and Protagonist Therapeutics, Inc. from 2014 to 2023. Eli Lilly, a giant in the industry, consistently reported SG&A expenses in the billions, peaking at approximately $6.9 billion in 2023. In contrast, Protagonist Therapeutics, a smaller player, saw its expenses grow from under $2 million in 2014 to over $33 million in 2023, marking a staggering increase of over 1,700%.
This data highlights the scale and growth dynamics within the pharmaceutical sector. While Eli Lilly's expenses reflect its established market presence, Protagonist's rising costs indicate its aggressive expansion strategy. Understanding these trends is vital for investors and industry analysts alike, as they offer insights into each company's operational focus and market strategy.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Novartis AG
Comparing SG&A Expenses: Eli Lilly and Company vs AstraZeneca PLC Trends and Insights
Comparing SG&A Expenses: Eli Lilly and Company vs Dr. Reddy's Laboratories Limited Trends and Insights
Selling, General, and Administrative Costs: Eli Lilly and Company vs Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Lantheus Holdings, Inc.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and ImmunityBio, Inc.
Eli Lilly and Company and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Protagonist Therapeutics, Inc. and Iovance Biotherapeutics, Inc.